“Specialty Drugs”

52 result(s)
Specialty
Know the Risks of Specialty Carve-out
Know the Cost and Care Risks of Specialty Carve-out More
Video
Cost Management
Strategy and Balance: Managing Costs for Pulmonary Arterial Hypertension
Managing Treatment Costs for Pulmonary Arterial Hypertension More
Briefing
Cost Management
A Breath of Fresh Air for Patients with Pulmonary Arterial Hypertension
New Dry Powder Inhalation Therapies for PAH in Pipeline More
Briefing
Specialty
The Role of Biosimilars in Lowering Specialty Costs
Biosimilars Can Be Part of a Strategy to Lower Specialty Drug Costs More
Briefing
Innovation
Patient-Reported Outcomes Help Ensure Drug Efficacy
Specialty Pharmacy Harnesses Patient-Reported Data to Drive Better Outcomes and Lower Costs More
Commentary
Drug Pipeline
More Treatments, Costs for Patients with Inflammatory Bowel Disease
As more treatments for inflammatory bowel disease are approved, payors can counter cost increases with comprehensive utilization management. More
Briefing
Drug Pipeline
New Migraine Drugs Near Approval
... More
Briefing
Cost Management
A Unique Focus for a PBM: Keeping Members Off Medication
Strategies for managing drug spend forpayors include helping members achieve better health and de-prescribing. More
Commentary
Cost Management
Specialty Spend: Balancing Affordability and Member Experience
Payor strategies for specialty drug spend must strike a balance between affordability and member experience. More
Commentary
Drug Pipeline
Biosimilars Help Support Members, Payors with Affordable Options
Biosimilars help to increase market competition. Balancing the use of biosimilars and biologics with strategic formulary decisions deliver lower costs. More
Briefing